| |
The physicians at Long Island and Queens Vitreoretinal Consultants are
committed to offering our patients the best care for their eye
conditions. To help us achieve this goal, we actively participate in
clinical trials to help develop new and better therapies.
Studies Currently Enrolling:
Ranibizumab (Lucentis®) For the treatment of Diabetic Macular Edema
Lucentis® vs Avastin® - A study comparing the efficacy of two medications used to treat wet AMD (CATT Study)
Coming Soon:
VGFTrap. Will investigate a novel medication for treating Macular Edema
Ranibizumab (Lucentis®) A study that will investigate alternative dosages of ranibizumab for the treatment of wet AMD
Past Experience:
Visudyne® - for wet AMD (VAM Study and VERITAS Study)
Lucentis® (Ranibizumab) for wet AMD (SAILOR Study and FOCUS Study)
- for Retinal Vein Occlusion (BRAVO)
Macugen® - for wet AMD
Posurdex® - for wet AMD
PK-C ß inhibitor for Diabetic Retinopathy
Vitrase® (hyaluronidase) for severe vitreous hemorrhage in Diabetic Retinopathy
Retaane® - for wet AMD
- for prevention of wet AMD in people at high risk
Squalamine Lactate for wet AMD
For more information about clinical trials contact our Study Coordinator,
Marianne Schlameuss, RN, at 516-466-0390 ext. 222.
|
|
